<DOC>
	<DOCNO>NCT01410435</DOCNO>
	<brief_summary>Since duration study IV iron IBD subject 4-12 week study need follow-up long term safety efficacy maintenance iron therapy . This study represent subject Lead-in Study ( P-Monofer-IBD-01 ) iron isomaltoside 1000 ( Monofer® ) ass long term safety iron isomaltoside 1000 ( Monofer® ) ability maintain stable haemoglobin IBD subject Iron Deficiency Anaemia ( IDA ) .</brief_summary>
	<brief_title>Safety Efficacy Extension Study Iron Isomaltoside 1000 ( Monofer® ) Subjects With Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Completed Leadin Study discontinue Leadin Study due intolerance oral iron . 2 . Life expectancy beyond 18 month Investigator 's judgement . 3 . Willingness participate inform consent . 1 . Discontinuation Leadin Study ( except due intolerance oral therapy ) . 2 . Any major protocol deviation Leadin Study . 3 . Pregnancy nurse [ To avoid pregnancy , woman postmenopausal , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product ( 5 day ) : Contraceptive pill , Intrauterine Devices ( IUD ) , contraceptive injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ] . 4 . Any medical condition , opinion Investigator , may cause subject unsuitable completion study place subject potential risk study . 5 . Patients HarveyBradshaw Index &gt; 8 Partial Mayo Score ( exclude Endoscopy Subscore ) &gt; 6 End Study Visit Leadin Study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>